AstraZeneca recently disclosed findings from two studies on its Symbicort (budesonide/formoterol fumarate dehydrate) inhaler formulated for the treatment of adults with chronic obstructive pulmonary disease (COPD) and pediatric patients with asthma. Results from ... Read more